Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Focused Fund median (28 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | JM Focused Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹93.33 |
| 12 Apr 2015 | ₹156.69 |
| 31 May 2016 | ₹156.85 |
| 19 Jul 2017 | ₹218.28 |
| 07 Sep 2018 | ₹245.90 |
| 27 Oct 2019 | ₹260.89 |
| 15 Dec 2020 | ₹274.05 |
| 03 Feb 2022 | ₹336.52 |
| 25 Mar 2023 | ₹332.73 |
| 12 May 2024 | ₹533.31 |
| 01 Jul 2025 | ₹593.02 |
| 20 Aug 2026 | ₹629.49 |
| Metric | JM Financial · Direct NAV ₹24.80 Very High risk ★★☆☆☆ | Category median Focused Fund · 28 funds |
|---|---|---|
| +7.68% | +5.84% | |
| +15.18% | +15.09% | |
| +15.48% | +13.35% | |
| +13.05% | +13.62% | |
| +14.45% | +15.49% | |
| +14.50% | — | |
| +15.83% | +16.73% | |
| +14.67% | +16.52% | |
| +15.37% | +16.05% | |
| Risk | ||
| 16.52% | 14.55% | |
| 0.53 | 0.57 | |
| 0.72 | 0.79 | |
| -37.37% | -34.05% | |
| Nifty 500 | — | |
| +2.66% | +3.16% | |
| 1.04 | 0.94 | |
| 112.6% | 104.9% | |
| 103.6% | 89.6% | |
| 1.32% | 1.06% | |
| ₹278.27Cr | ₹2,441Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹1.00K | — | |
| 78% | 32% | |
| Ruchi Fozdar | — | |
| 02 Jan 2013 | — | |
| 28 | — | |
| 44.2% | — | |
| 1.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.